The antibody screen
14 min
- Explain why group O reagent cells are used for unexpected-antibody screening
- Name the antibodies a negative screen can miss and the checks that still apply
- Accept or reject a crossmatch sample by its age and the transfusion and pregnancy history
Try first
Get the idea
Group O screening cells
The antibody screen tests the patient's plasma against two or three group O reagent red cells with known antigen profiles. Group O cells lack A and B, so the patient's expected anti-A and anti-B have nothing to react with. A reaction points to an unexpected antibody.1,2
Across the lot, the cells carry D, C, E, c, e, K, k, Fya, Fyb, Jka, Jkb, Lea, Leb, P1, M, N, S and s. Each cell is tested on its own, and the lot's antigen profile lists what each cell carries.3
What a negative screen means
A nonreactive screen shows no antibody detectable against the antigens on those cells, under those test conditions.1,4 It can miss:
- a weak antibody, or one that has fallen below detection since it formed
- an antibody that shows dosage, when the cells carry only a single dose of its antigen
- an antibody to a low-prevalence antigen that the cells lack and a donor unit carries
The patient's antibody history still decides unit selection when today's screen is nonreactive. A recorded clinically significant antibody calls for antigen-negative red cells and an antiglobulin crossmatch.1,2
How old a specimen can be
Transfusion and pregnancy can start a new antibody within days. Federal rules require a specimen less than 3 days old when the patient was transfused or pregnant in the preceding 3 months.5 The collection date is day 0, and the specimen expires at midnight on day 3. AABB standards apply the same limit when the history is unknown or uncertain.1,2 A longer interval needs a reliable negative history and a defined facility policy.2,6
References
- Bloch EM, Campbell-Lee S, McKenna DH Jr, Montemayor-Garcia C, Schwartz J, Shaz B, Storry J, eds. Technical Manual. 22nd ed. AABB; 2026.
- Association for the Advancement of Blood & Biotherapies. Fundamental Standards for Blood Collection and Transfusion. 2nd ed. AABB; 2025. Accessed September 27, 2026.
- Testing of source material, 21 CFR §660.33 (2026). Accessed September 27, 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-660/subpart-D/section-660.33
- Immucor, Inc. Panoscreen Reagent Red Blood Cells Package Insert. US Food and Drug Administration. Accessed September 27, 2026.
- Compatibility testing, 21 CFR §606.151 (2026). Accessed September 27, 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-606/subpart-C/section-606.151
- Association for the Advancement of Blood & Biotherapies. Standards for Blood Banks and Transfusion Services. 35th ed. AABB; 2026. Accessed September 27, 2026.
Watch one
Tobias Lindqvist, 66, is typed and screened before hip surgery. His record shows anti-Jka identified 2 years ago. Today's three-cell screen reads:
The check cells agglutinated in every tube. What does the screen show, and which red cells does he receive?
| Cell | D | C | E | c | e | K | k | Fya | Fyb | Jka | Jkb | M | N | S | s | P1 | Lea | Leb | 37 | AHG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | + | + | 0 | 0 | + | + | + | + | 0 | + | + | + | 0 | + | + | + | 0 | + | 0 | 0 |
| 2 | + | 0 | + | + | 0 | 0 | + | 0 | + | 0 | + | 0 | + | 0 | + | 0 | + | 0 | 0 | 0 |
| 3 | 0 | 0 | 0 | + | + | 0 | + | + | + | + | 0 | + | + | 0 | + | + | 0 | + | 0 | 0 |
- Check validity first. Every cell is 0 at 37 °C and the antiglobulin phase, and the check cells agglutinated.
A negative tube reading counts only when the check cells show the antihuman globulin was active.
- Read the Kidd antigens. Cell 3 is Jk(a+b−), a double dose of Jka, and it is nonreactive.
A double-dose cell gives a weak Kidd antibody its best chance to react.
- State what the screen supports. No anti-Jka is detectable today.
Kidd antibodies can fall below detection and return within days of re-exposure.
- Pull up the record. The anti-Jka identified 2 years ago stays on it.
A recorded clinically significant antibody decides unit selection whatever today's screen shows.
- Select Jk(a−) red cells and crossmatch them through the antiglobulin phase.
A history of a clinically significant antibody removes the ABO-only crossmatch pathway.
Your turn
Use it
- Hollis Varga, 58, a long-haul trucker, MRN 7730418, arrives unresponsive after a highway crash. No transfusion history can be found.
- A type and screen was collected on Sunday at 14:00.
- On Friday, surgery asks for 2 red cell units on that specimen.
- The facility's policy allows a specimen up to 14 days old for a patient with a reliable negative history.
| Cell | D | C | E | c | e | K | k | Fya | Fyb | Jka | Jkb | M | N | S | s | P1 | Lea | Leb | 37 | AHG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | + | + | 0 | 0 | + | + | + | + | + | + | + | + | + | + | 0 | + | 0 | + | 0 | 0 |
| 2 | + | 0 | + | + | 0 | 0 | + | + | 0 | 0 | + | 0 | + | 0 | + | + | + | 0 | 0 | 0 |
The clue that settled this case is his unknown history. It set the 3-day limit on both specimens. It also means the nonreactive screen, with only a single dose of Jka on its cells, is the whole of what is known about his antibodies.
Results
- Explain why group O reagent cells are used for unexpected-antibody screening
- Name the antibodies a negative screen can miss and the checks that still apply
- Accept or reject a crossmatch sample by its age and the transfusion and pregnancy history
To review
6 questions from this step will come back in Review.
Keep
Sources checked
The rest of this step
A short briefing, a demonstration at the bench, 3 practice problems and a short case.
A free account opens the rest and keeps your progress.